Table 3.
Frequency and expression level (G-MFI) of NK cell receptors.
| RHI-LVL | RHI-HVL | LTNP | Progressors | Healthy controls | |||
|---|---|---|---|---|---|---|---|
| NATURAL CYTOTOXICITY RECEPTORS | |||||||
| NKp44 | Frequency (%) | Median | 26.75 | 23.05 | 29.7 | 25.4 | 0.15 |
| IQR | 6.2–31.4 | 4.8–28.2 | 5–35.6 | 1.33–31.4 | 0.1–0.4 | ||
| G-MFI | Median | 357 | 231.5 | 452.5 | 116 | 103 | |
| IQR | 320–426 | 115–352 | 380–550 | 106–125 | 108–111 | ||
| NKp30 | Frequency (%) | Median | 46.68 | 40.505 | 52.15 | 43.27 | 55.5 |
| IQR | 19.1–51.7 | 13.6–65 | 27.6–70 | 15.6–60.4 | 23.2–83 | ||
| G-MFI | Median | 324.5 | 218.5 | 458 | 256.5 | 382 | |
| IQR | 240–355 | 142–348 | 414–567 | 228–303 | 222–376 | ||
| NKp46 | Frequency (%) | Median | 78.63 | 76.3 | 86.8 | 64.2 | 84 |
| IQR | 33.3–99 | 58.5–95.5 | 71.1–98.2 | 45.5–94.3 | 51.2–71.9 | ||
| G-MFI | Median | 461 | 340.7 | 740 | 410 | 525 | |
| IQR | 332–902 | 273–430 | 645–827 | 325–538 | 436–660 | ||
| NKG2 FAMILY OF RECEPTORS | |||||||
| NKG2D | Frequency (%) | Median | 89.85 | 44.6 | 74.11 | 45.5 | 64.56 |
| IQR | 69.9–94.3 | 24.6–58.7 | 43 –81.7 | 36.6–62.5 | 32.6–78.1 | ||
| G-MFI | Median | 377 | 185 | 622 | 124 | 571 | |
| IQR | 248–850 | 115–222 | 391–1237 | 165–184 | 416–917 | ||
| NKG2C | Frequency (%) | Median | 42.59 | 57 | 47.4 | 43.3 | 24.5 |
| IQR | 34.7–52 | 46.1–65.4 | 42.9–70.2 | 23.8–59.6 | 18.7–61 | ||
| G-MFI | Median | 439.4 | 425.3 | 1117 | 465 | 798 | |
| IQR | 245–593 | 318–508 | 709–3096 | 418–644 | 764–909 | ||
| NKG2A | Frequency (%) | Median | 27.2 | 34.7 | 35.3 | 24.9 | 9 |
| IQR | 21–41.7 | 27–43 | 27.2–55.4 | 12.78–42.5 | 4.53–11 | ||
| G-MFI | Median | 486 | 598 | 460.5 | 444 | 814 | |
| IQR | 258.2–587 | 382–656.6 | 335–1626 | 420–648 | 669.2–1330 | ||
| EARLY ACTIVATION MARKERS | |||||||
| HLA-DR | Frequency (%) | Median | 31.8 | 24.9 | 33.8 | 25.7 | 12.2 |
| IQR | 19.9–41.7 | 7.3–40.7 | 4.8–39.6 | 6.32–44.5 | 4.7–23.6 | ||
| G-MFI | Median | 320 | 142 | 636 | 140 | 405 | |
| IQR | 188–587 | 117–482 | 469–813 | 128–242 | 236–763 | ||
| CD69 | Frequency (%) | Median | 32.9 | 30.92 | 13.3 | 9.68 | 4.555 |
| IQR | 3.43–35.7 | 1.11–66 | 7.28–13.7 | 2.81–63.4 | 2.93–8 | ||
| G-MFI | Median | 150 | 203 | 462.5 | 167 | 407.75 | |
| IQR | 129.5–187 | 182.5–204 | 442–491.5 | 132–206 | 283.6–452.2 | ||
| INHIBITORY RECEPTORS | |||||||
| CD158b | Frequency (%) | Median | 51.3 | 56.2 | 40.1 | 47.5 | 19.9 |
| IQR | 43–62.3 | 50.2–59.1 | 27.6–51.4 | 19.1–54.8 | 10.3–26 | ||
| G-MFI | Median | 478 | 458.5 | 1085 | 193 | 905 | |
| IQR | 424.6–505 | 337.5–610 | 870–1178 | 152–278 | 708.5–1054.2 | ||
| ILT2 | Frequency (%) | Median | 31 | 24.95 | 33.05 | 28.2 | 2.75 |
| IQR | 9–39.9 | 4.4–34.8 | 13.6–56 | 8.21–35 | 1.62–8.2 | ||
| G-MFI | Median | 127 | 136.5 | 1196 | 628.9 | 541 | |
| IQR | 120–133.5 | 120–171.5 | 647–2664 | 326.7–647 | 509–958 | ||